Oxford Nanopore Technologies (OTCMKTS:ONTTF) and Tango Therapeutics (NASDAQ:TNGX) Head-To-Head Survey

Oxford Nanopore Technologies (OTCMKTS:ONTTF) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Insider and Institutional Ownership

79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Oxford Nanopore Technologies and Tango Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0	0	3	0	3.00
Tango Therapeutics	1	2	13	0	2.75

Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 93.48%. Given Tango Therapeutics’ higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Oxford Nanopore Technologies.

Earnings and Valuation

This table compares Oxford Nanopore Technologies and Tango Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	N/A	N/A	N/A	N/A	N/A
Tango Therapeutics	$62.38 million	60.72	-$101.59 million	($0.85)	-26.43

Oxford Nanopore Technologies has higher earnings, but lower revenue than Tango Therapeutics.

Profitability

This table compares Oxford Nanopore Technologies and Tango Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	N/A	N/A	N/A
Tango Therapeutics	N/A	-25.75%	-23.36%

Summary

Tango Therapeutics beats Oxford Nanopore Technologies on 5 of the 8 factors compared between the two stocks.

About Oxford Nanopore Technologies

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company operates in Life Science Research Tools and Covid Testing segments. It offers MinION, a portable device for DNA and RNA; GridION, a flexible and self-contained benchtop nanopore sequencer to run and analyse up to five MinION or Flongle flow cells; MinION Mk 1C, a nano pore-based sequencer with analysis software and connectivity for self-contained and portable sequencing; Flongle, an adapter for MinION or GridION that enables DNA sequencing or cDNA sequencing on smaller and single-use flow cells; and PromethION 2 Solo, a sequencer for two PromethION flow cells. The company also provides PromethION 2, a self-contained benchtop nanopore sequencer; PromethION 24, which provides single or multiple users with access to terabases of sequencing data; PromethION 48, a sequencing device with high-output flow cells; VolTRAX, an automated library prep for nanopore analyses; and Q-Line, a sequencing for applied applications, as well as products for SAR-Cov-2 testing. Its platform enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.